CN107405403B - 用于治疗纤维化和腹膜炎的塞尼克韦罗 - Google Patents

用于治疗纤维化和腹膜炎的塞尼克韦罗 Download PDF

Info

Publication number
CN107405403B
CN107405403B CN201580076576.9A CN201580076576A CN107405403B CN 107405403 B CN107405403 B CN 107405403B CN 201580076576 A CN201580076576 A CN 201580076576A CN 107405403 B CN107405403 B CN 107405403B
Authority
CN
China
Prior art keywords
cvc
liver
group
cenicriviroc
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580076576.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107405403A (zh
Inventor
E·列菲伏尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tobira Therapeutics Inc
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of CN107405403A publication Critical patent/CN107405403A/zh
Application granted granted Critical
Publication of CN107405403B publication Critical patent/CN107405403B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580076576.9A 2015-02-10 2015-09-22 用于治疗纤维化和腹膜炎的塞尼克韦罗 Expired - Fee Related CN107405403B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114304P 2015-02-10 2015-02-10
US62/114,304 2015-02-10
PCT/US2015/051467 WO2016130179A1 (en) 2015-02-10 2015-09-22 Cenicriviroc for the treatment of fibrosis

Publications (2)

Publication Number Publication Date
CN107405403A CN107405403A (zh) 2017-11-28
CN107405403B true CN107405403B (zh) 2021-04-20

Family

ID=56614560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580076576.9A Expired - Fee Related CN107405403B (zh) 2015-02-10 2015-09-22 用于治疗纤维化和腹膜炎的塞尼克韦罗

Country Status (15)

Country Link
US (3) US20180110754A1 (enExample)
EP (1) EP3256124B1 (enExample)
JP (2) JP6676660B2 (enExample)
KR (1) KR20170113596A (enExample)
CN (1) CN107405403B (enExample)
AU (1) AU2015382376B2 (enExample)
BR (1) BR112017016388A2 (enExample)
CA (1) CA2975445A1 (enExample)
ES (1) ES2864767T3 (enExample)
HK (1) HK1247558A1 (enExample)
IL (1) IL253617A0 (enExample)
MX (1) MX2017010277A (enExample)
RU (1) RU2722641C2 (enExample)
SG (1) SG11201706028RA (enExample)
WO (1) WO2016130179A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
CN112266392A (zh) 2014-12-23 2021-01-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
WO2017223155A1 (en) 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞，其制备方法及抗纤维化的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000922A1 (en) * 2011-06-27 2013-01-03 Universite Pierre Et Marie Curie (Paris 6) Ccr2 antagonist peptides
WO2014186581A1 (en) * 2013-05-15 2014-11-20 Tobira Therapeutics, Inc. Cenicriviroc compositions and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
JP6263814B2 (ja) * 2013-03-05 2018-01-24 国立大学法人 岡山大学 細胞死抑制剤及び新規化合物
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000922A1 (en) * 2011-06-27 2013-01-03 Universite Pierre Et Marie Curie (Paris 6) Ccr2 antagonist peptides
WO2014186581A1 (en) * 2013-05-15 2014-11-20 Tobira Therapeutics, Inc. Cenicriviroc compositions and methods of making and using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis;European Association for the Study of the Liver;《Journal of Hepatology》;Elsevier ScienceDirect;20100930;第53卷(第3期);397-417 *
Tobira Therapeutics Presents Data Supporting Anti-Fibrotic Activity of Cenicriviroc in Liver Disease Models at The Liver Meeting 2013;Tobira Therapeutics;《AASLD Annual Meeting 2013》;20131104;第1页最后1段，第2页第1-5段 *
Tobira Therapeutics.Tobira Therapeutics Presents Data Supporting Anti-Fibrotic Activity of Cenicriviroc in Liver Disease Models at The Liver Meeting 2013.《AASLD Annual Meeting 2013》.2013,第1页最后1段，第2页第1段、第4段. *
药物性肝损害与纤维化;蔡卫民;《药品评价》;20071228;第4卷(第6期);395,396 *

Also Published As

Publication number Publication date
WO2016130179A1 (en) 2016-08-18
CA2975445A1 (en) 2016-08-18
JP2018505218A (ja) 2018-02-22
RU2722641C2 (ru) 2020-06-02
RU2017130289A3 (enExample) 2019-04-22
CN107405403A (zh) 2017-11-28
EP3256124A4 (en) 2018-09-26
US20200360347A1 (en) 2020-11-19
AU2015382376A1 (en) 2017-08-17
JP6676660B2 (ja) 2020-04-08
US20190343806A1 (en) 2019-11-14
KR20170113596A (ko) 2017-10-12
EP3256124A1 (en) 2017-12-20
JP2020111586A (ja) 2020-07-27
SG11201706028RA (en) 2017-08-30
IL253617A0 (en) 2017-09-28
AU2015382376B2 (en) 2021-07-01
US20180110754A1 (en) 2018-04-26
BR112017016388A2 (pt) 2018-03-27
MX2017010277A (es) 2017-12-07
HK1247558A1 (zh) 2018-09-28
EP3256124B1 (en) 2020-12-23
ES2864767T3 (es) 2021-10-14
RU2017130289A (ru) 2019-03-12

Similar Documents

Publication Publication Date Title
US20200368247A1 (en) Cenicriviroc for the treatment of fibrosis
JP2020196750A (ja) 線維症を処置するためのセニクリビロック併用療法
US20200268768A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210420